Beam Therapeutics to Participate in Upcoming May Investor Conferences

Rhea-AI Summary

Beam Therapeutics (Nasdaq: BEAM), a biotech firm focused on precision genetic medicines, announced CEO John Evans will speak at two investor conferences in May 2022. The events are the BofA Securities 2022 Healthcare Conference on May 11, at 2:00 PM PT in Las Vegas, and the RBC Capital Markets Global Healthcare Conference on May 17, at 2:35 PM ET in NYC. Live webcasts will be available on their website and archived for 60 days. Beam is advancing gene editing technologies, particularly base editing, to develop therapies for serious diseases.

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in fireside chats during the following May investor conferences:

• BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 2:00 p.m. PT in Las Vegas; and,
• 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022, at 2:35 p.m. ET in NYC.

Live webcasts will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the presentation.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contacts:

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com 

Media:
Dan Budwick
1AB
dan@1abmedia.com 

FAQ

When is Beam Therapeutics participating in investor conferences in May 2022?

Beam Therapeutics will participate in the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 2:00 PM PT, and the RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 2:35 PM ET.

Where can I watch the Beam Therapeutics investor conference presentations?

Live webcasts of the Beam Therapeutics presentations will be available on their website and archived for 60 days after the events.

What is the focus of Beam Therapeutics?

Beam Therapeutics focuses on developing precision genetic medicines using advanced gene editing technologies, particularly base editing.

What technology is Beam Therapeutics known for?

Beam Therapeutics is known for its proprietary base editing technology, which allows precise genetic modifications without double-stranded DNA breaks.

What is the stock symbol for Beam Therapeutics?

The stock symbol for Beam Therapeutics is BEAM, and it is traded on Nasdaq.